SShasqi uses its CAPAC platform to activate cancer drugs directly at the tumor by pairing a tumor-targeting binder with a systemically administered protodrug, so the active drug forms mainly at the tumor site. Its lead asset combines a CEACAM5-targeting binder with an MMAE protodrug, and the platform is modular enough to handle chemotherapy or radiopharmaceutical payloads, as seen in SQ3370 with an intratumoral biopolymer and doxorubicin in early human studies. The approach separates targeting from activation to limit exposure of healthy tissue and extends to multiple payloads, including collaborations like the Johnson & Johnson Enterprise Innovation program. The goal is to improve cancer outcomes by localizing drug activation at tumors and advancing the CAPAC platform toward clinical impact.
Work here?Claim your company
Industries
Company Size
11-50
Company Stage
Series B
Total Funding
$65.2M
Headquarters
San Francisco, CA
Founded
2015
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$65.2M
Above
Industry Average
Funded Over
7 Rounds
Industry standards
Shasqi - Funding & investors. Last updated: March 17, 2026 Shasqi's funding rounds. Shasqi has raised a total of $60M over 11 funding rounds: 1 Seed, 2 Early-Stage and 8 Grant (prize money) round s. Shasqi's largest funding round so far was a Series B round for $***** in Nov 2021. Here is the list of all funding rounds of Shasqi: | Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors | | Sep 06, 2024 | 2750030 | Grant (prize money) | 4194622 | 4195538 | 5713887 | 8696140 | | Sep 01, 2023 | 3393176 | Grant (prize money) | 5418205 | 9043238 | 3592703 | HHS | | Dec 08, 2021 | 5743177 | Grant (prize money) | 8538904 | 6101996 | 4085788 | National Cancer Institute | | Nov 11, 2021 | 5988582 | Series B | 5737698 | 2342621 | 3215134 | Bill Rieflin | | Sep 16, 2021 | 3705629 | Grant (prize money) | 1334157 | 1950403 | 7256795 | HHS | | Apr 27, 2021 | 6917293 | 823183 | 6481066 | 3557384 | 1807102 | 7440397 | | Apr 01, 2021 | 8188633 | 848533 | 2038637 | 5417071 | 2918478 | 4175337 | | Oct 31, 2019 | 5001812 | 456832 | 5959342 | 4698135 | 2809778 | 8683357 | | Apr 01, 2017 | 3053491 | 479762 | 1802011 | 7379024 | 9628442 | 9119013 | | Jan 01, 2016 | 5281867 | 355739 | 8541574 | 8609781 | 6987622 | 3871008 | | 2015 | 4173 | 63 | 1957 | 6934 | 8673 | 5123 | Shasqi's investors. Shasqi has total 8 investor s, 6 are institutional investors including Y Combinator and 5 others, Shasqi has 2 Angel investors including Bill Rieflin and Juan Jaen. Here is the list of institutional investors of Shasqi: * National Cancer Institute, located in Bethesda (United States), made their first investment in Shasqi on Dec 08, 2021 in its Grant (prize money) round. * HHS, located in Washington, DC (United States), made their first investment in Shasqi on Sep 16, 2021 in its Grant (prize money) round. Are you a Founder? FAQs about Shasqi's funding and investors. Shasqi has raised a total of $60M over 11 rounds. Shasqi's largest funding round was a Series B round held on Nov 11, 2021 for $*****. * 8 Grant (prize money) rounds * 2 Early-Stage rounds * 1 Seed round Shasqi has a total of 8 investors. 6 are Institutional investors and 2 are Angel investors. Explore latest companies that raised funding recently * Athler - raised a funding of $6.69M in Series B round held on Mar 17, 2026. * SmartSolar - raised a funding of $1.3M in Conventional Debt round held on Mar 17, 2026. * Sequential Bio - raised a funding of $3.5M in Series A round held on Mar 17, 2026. * Bamboobox - raised a funding of $6.6M in Series A round held on Mar 17, 2026. * thezoomiesstore.in - raised a funding of $541K in Seed round held on Mar 17, 2026.
SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced that Founder and Chief Executive Officer José M. Mejía Oneto, MD, PhD, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday January 16th at 11:00am Pacific Time / 2:00pm Eastern time in conference hall Elizabethan C.Dr. Mejía Oneto will be sharing emerging data from Shasqi's novel Click Activated Protodrugs Against Cancer (CAPAC®) technology, a pre-targeting approach that separates the binder from the payload and reunites them at the tumor using in vivo click chemistry."We are honored to present at this year's J.P
SAN FRANCISCO, April 5, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi"), a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced it will present five posters on the company's novel tumor-targeted drug activation approach at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, April 5-10, 2024.The posters will describe data generated with Shasqi's CAPAC® (Click Activated Protodrugs Against Cancer) approach. CAPAC uses 2022 Nobel Prize winning technology, click chemistry, to selectively activate high doses of cancer drugs directly at the tumor, minimizing toxicity to healthy cells and potentially improving the therapeutic index by dramatically altering the exposure. This approach overcomes many limitations of antibody-drug conjugates (ADCs)."We are looking forward to sharing new data from the Shasqi pipeline at AACR," said Shasqi Vice President of Research, Travis Biechele, Ph.D. "It is exciting to see data showing that we can effectively activate cancer drugs at the tumor using antigen-bound activators, resulting in sustained tumor regression."Shasqi is advancing a pipeline of assets based on validated targets and payloads. The posters presented at the AACR meeting will show preclinical efficacy and safety data for assets targeting HER2, TROP2, and NECTIN-4, each paired with either an MMAE or exatecan payload.PresentationsAbstracts are available and can be viewed on the AACR website.Monday, April 8 between 9 AM - 12:30 PM PSTClick chemistry enabled selective activation of highly cytotoxic MMAE payload at tumors using TROP2 targeting agentLead Author: George Coricor, Ph.D.Poster Section 28, Poster Board: 13Wednesday, April 10 between 9 AM - 12:30 PM PSTTumor targeted activation of an attenuated exatecan protodrug through Click Chemistry demonstrates efficacy in murine tumor studiesLead Author: Sangeetha Srinivasan , Ph.D., Ph.D
SAN FRANCISCO, Jan. 4, 2024 /PRNewswire/ - Shasqi, Inc. ("Shasqi") a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced the expansion of its board with the appointment of Pamela M. Klein, M.D., and Mark McCamish M.D., Ph.D.
Shasqi, Inc., a clinical-stage biotechnology company with a mission to enhance the efficacy of cancer drugs through click chemistry, has recently announced the expansion of its ongoing research collaboration with Johnson & Johnson Enterprise Innovation Inc.
Find jobs on Simplify and start your career today
We update Shasqi's jobs every few hours, so check again soon!Browse all jobs
Industries
Company Size
11-50
Company Stage
Series B
Total Funding
$65.2M
Headquarters
San Francisco, CA
Founded
2015
Find jobs on Simplify and start your career today
We update Shasqi's jobs every few hours, so check again soon!Browse all jobs